$145 Million is the total value of Stonepine Capital Management, LLC's 25 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | Sell | AMARIN CORP PLC -ADRspons adr new | $18,044,000 | -8.2% | 930,604 | -1.7% | 12.42% | +9.9% |
| ALIM | Sell | ALIMERA SCIENCES INC | $5,731,000 | -16.6% | 6,439,498 | -0.7% | 3.95% | -0.2% |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $5,553,000 | -20.5% | 871,762 | -27.5% | 3.82% | -4.8% |
| HTGM | Sell | HTG MOLECULAR DIAGNOSTICS | $4,624,000 | -34.8% | 2,785,585 | -1.8% | 3.18% | -21.9% |
| CTIC | Sell | CTI BIOPHARMA CORP | $3,355,000 | -13.6% | 3,904,400 | -2.4% | 2.31% | +3.5% |
| FOMX | Sell | FOAMIX PHARMACEUTICALS LTD | $1,550,000 | -43.4% | 651,211 | -10.8% | 1.07% | -32.3% |
| MTNB | Sell | MATINAS BIOPHARMA HOLDINGS I | $573,000 | -73.8% | 668,615 | -66.7% | 0.40% | -68.6% |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $508,000 | -45.5% | 162,244 | -13.3% | 0.35% | -34.7% |
| COLL | Exit | COLLEGIUM PHARMACEUTICAL INC | $0 | – | -60,045 | -100.0% | -0.52% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -98,860 | -100.0% | -0.58% | – |
| DMAC | Exit | DIAMEDICA THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.65% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -500,000 | -100.0% | -0.85% | – |
| CHMA | Exit | CHIASMA INC | $0 | – | -300,000 | -100.0% | -0.90% | – |
| EBS | Exit | EMERGENT BIOSOLUTIONS INC | $0 | – | -46,800 | -100.0% | -1.36% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -4,074,944 | -100.0% | -3.30% | – |
| Exit | AEGERION PHARMACEUTICALSAEGR 2 08/15/19note 2.000% 8/1 | $0 | – | -9,000,000 | -100.0% | -3.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.